Clinical Trials
34 trialsReal-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
COBRA
Istituto Oncologico Veneto IRCCS
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
TOG-SAFRADJU
Ankara University
CardioSwitch
Helsinki University Central Hospital
NeoTNBCX
Peking University People's Hospital
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure
Institute of Oncology Ljubljana
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
The First Affiliated Hospital with Nanjing Medical University
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
The First Affiliated Hospital of Zhengzhou University
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
China Medical University, China
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
Sun Yat-sen University
ADAPTA
Fondazione Poliambulanza Istituto Ospedaliero
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
Fujian Medical University Union Hospital
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
Peking Union Medical College Hospital
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Fudan University
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy
UNC Lineberger Comprehensive Cancer Center
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
Beijing Friendship Hospital
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
Peking University Cancer Hospital & Institute
BJCC-R01
Peking University Cancer Hospital & Institute
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study on Skin Microbiome of HFS
First Affiliated Hospital of Harbin Medical University
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
AVOCETTE
University Hospital, Caen
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
King Faisal Specialist Hospital & Research Center
MATURE
International Group of Endovascular Oncology
Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer
Fudan University
Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients
General Hospital of Ningxia Medical University
microRNA of Human Epidermal Growth Factor Receptor 2 (HER2)Positive Patient Treated With Herceptin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Hoosier Cancer Research Network
Chemotherapeutic Agents in Brain/Breast
Case Comprehensive Cancer Center
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
Fudan University
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
King Faisal Specialist Hospital & Research Center